Navigation Links
Oramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes
Date:1/10/2012

JERUSALEM, January 10, 2012 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.

The complexity of the development and progression of diabetes often requires concomitant treatments, designed to simultaneously target the numerous underlying pathological triggers. The combined use of these two drugs has recently been evaluated in animals and showed improved blood glucose regulation when compared to the administration of each drug separately.

These formulations have been designed to allow for oral delivery of drugs currently only available in injectable forms.  Both drugs are currently being independently assessed in human clinical trials.  An oral delivery system may substantially increase patient compliance, especially at the earliest of stages of treatment, which would have a meaningful outcome on quality of life and workplace productivity.

According to a report by Medtech Insight, diabetes affects nearly 24 million people in the U.S. and an estimated 246 million adults worldwide. Being one of the most expensive diseases, it costs the US healthcare system more than $130 billion per year and the market for direct pharmaceutical care is close to $15 billion.

"This intriguing development is part of the company's strategy to further expand our pipeline in a very focused manner. Expansion of Oramed Pharmaceuticals' intellectual property portfolio and related programs will further enhance our ability to offer a higher return on investment to our shareholders as we continue pioneering advances in drug delivery options," stated Oramed  Pharmaceuticals' CEO, Mr. Nadav Kidron.

Each of the formulations alone is currently patent pending in the US and other key markets around the world. ORMD-0801 is an orally ingestible insulin capsule and has recently demonstrated a favorable effect when evaluated in Phase II clinical trials for its effectiveness in treating Type II diabetes. ORMD-0901 is a glucagon-like peptide-1 analog, a gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. Oramed commenced human clinical trials for ORMD-0901 following successful pre-clinical results. 

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem. For more information, please visit http://www.oramed.com 

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements. 

Company Contact:
Oramed Pharmaceuticals
Tara Horn
Cell: +972-54-334-318
Office: +972-2-566-0001       
Email: tara@oramed.com 


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals Announces Successful Phase 1 Clinical Trial Results for EnteraBio
2. Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011
3. Oramed Pharmaceuticals to Present at Rodman & Renshaw 13th Annual Global Investment Conference
4. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
5. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
6. Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
7. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
8. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
9. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
10. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
11. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... 2035" report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, ... growing market of deep learning solutions within the healthcare domain. Primarily ... as a novel solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... , March 24, 2017 ... the industry including definitions, classifications, applications and industry chain ... international market including development history, competitive landscape analysis, and ... ... industry spread across 105 pages providing 10 company profiles ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier ... professionals caring for those suffering from the full spectrum of disordered eating, announced today ... disorders professionals from nearly all 50 states and several countries converged on the Green ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... wanted to create a communications platform that positions them as the go-to thought ... ONS reinvented their online publication as an always-on, always-fresh news, views and advocacy ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate themselves on current ... practices, goods, services, and societal issues tend to appreciate and love the "Informed" series, ... of utilizing running events for causes around the world. , Running for ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ ... #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion with God. ... with God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
Breaking Medicine News(10 mins):